{"title":"75th anniversary of the National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation","authors":"A. Editorial","doi":"10.20996/1819-6446-2023-2986","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2986","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"2020 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139285934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Y. Borovkova, V. K. Kurashin, A. Tokareva, T. Bakka, N. K. Pershina, E. S. Timoshchenko, A. A. Nekrasov, E. A. Ovchinnikova, N. N. Savickaya, M. A. Mironov, Y. Balanova, A. Imaeva, A. Kontsevaya
{"title":"Gender and age features of dyslipidemia in the population of the Nizhny Novgorod region","authors":"N. Y. Borovkova, V. K. Kurashin, A. Tokareva, T. Bakka, N. K. Pershina, E. S. Timoshchenko, A. A. Nekrasov, E. A. Ovchinnikova, N. N. Savickaya, M. A. Mironov, Y. Balanova, A. Imaeva, A. Kontsevaya","doi":"10.20996/1819-6446-2023-2951","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2951","url":null,"abstract":"Aim. To study the gender and age characteristics of dyslipidemia in the population of the Nizhny Novgorod region.Material and methods. A total of 2501 people aged 35-74 among the population of the Nizhny Novgorod region were examined, selected by stratified multi-stage random sampling. The study was performed as part of the third epidemiological study ESSE-RF3. All respondents underwent an anthropometric survey, a questionnaire to identify chronic non-communicable diseases and related risk factors. The following laboratory tests were performed: total cholesterol (TC), low-density lipoproteins (LDL-C), high-density lipoproteins (HDL-C), triglycerides (TG). Among the entire cohort of patients at the time of blood sampling, 276 people (11,0%) were receiving lipid-lowering drugs. They were excluded from further analysis. Hypercholesterolemia (HCL) was recorded with a total cholesterol ≥5,0 mmol/l, an increased level of LDL-C — with a level ≥3,0 mmol/l, hypertriglyceridemia (HTG) — with a TG ≥1,7 mmol/l, a reduced level of HDL-C — with a level in males ≤1,0 mmol/l, in women ≤1,2 mmol/l.Results. The prevalence of HCL was 65,1%. In the young cohort (40-44 years), men were significantly more likely to have hypercholesterolemia, but in the middle (50-54 years) and older (60 years or more) age groups, this lipid metabolism disorder was observed with greater frequency among females. In addition, 68,9% of the respondents had elevated LDL-C levels. When studying the prevalence of this type of dyslipidemia in different age groups among men and women, a similar trend can be noted with similar TC values, but significant gender differences in the prevalence of elevated LDL-C levels l were revealed only in the 60-64 and 65-69 years groups. The prevalence of HTG among the adult population of the Nizhny Novgorod region was 42,6%. Among the 35-49 years and 55-59 years age groups, the prevalence of elevated TG levels was significantly more common among men. The incidence of decreased HDL-C levels was 13,3%. This type of dyslipidemia was significantly more often detected among men only in the youngest subgroup (35-39 years).Conclusion. Among the population of the Nizhny Novgorod region, hypercholesterolemia occurred in 65,1% of respondents, an increased level of LDL-C — in 68,9%, a HTG — in 42,6%, a reduced level of HDL-C — in 13,3%. The data obtained determine a high cardiovascular risk and require the development of prevention and treatment measures for lipid metabolism disorders.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"12 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139286911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Bochkareva, E. K. Butina, N. Bayramkulova, I. V. Kim, O. Molchanova, E. M. Filichkina, E. Yarovaya, V. Metelskaya, O. Drapkina
{"title":"Association of breast arterial calcification and carotid atherosclerosis as a marker of cardiovascular risk","authors":"E. Bochkareva, E. K. Butina, N. Bayramkulova, I. V. Kim, O. Molchanova, E. M. Filichkina, E. Yarovaya, V. Metelskaya, O. Drapkina","doi":"10.20996/1819-6446-2023-2950","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2950","url":null,"abstract":"Aim. To study the relationship between breast arterial calcification (BAC) and the presence and severity of carotid atherosclerosis.Material and methods. We analyzed 4274 digital mammograms of women who underwent diagnostic mammography. In addition to the standard diagnosis of breast diseases, BAC was assessed in all mammograms. The study included 198 women aged 40-74 years, who made up 2 groups with and without BAC, each consisting of 99 people, formed on a case-control basis. The severity of BAC was assessed by a 12-point score. Duplex ultrasound of extracranial arteries determined plaque presence, the severity of CA stenosis (in percent) and intima-media thickness (IMT). All women underwent physical and laboratory examinations, electrocardiography, and were interviewed using a questionnaire assessing socio-demographic data, menopausal status, risk factors, and diseases.Results. The groups did not differ in lipid levels, blood glucose, body mass index, incidence of hypertension, diabetes, or smoking. Women with BAC had a higher incidence of menopause (94,9% vs 84,8%, p=0,033), coronary artery disease (13,1% vs 4,2%, p=0,039) and osteoporosis (18,2% vs 6,1%, p=0,016) in history. In women with BAC, at least one carotid plaque was observed significantly more often than in those without BAC — in 79,8% and 60,6% of cases, respectively (p=0,005). Women with BAC compared with women without BAC had a greater plaque number (1,0 [1,0; 3,0] vs, 1,0 [1,0; 2,0], p<0,001) and a more severe carotid stenosis, assessed by maximum (25,0 [17,5; 35,0] vs 20,0 [0,0; 27,5], p=0,001), total (30,0 [20,0; 92,5] vs 25,0 [0,0; 50,0], p<0,001) and mean arterial stenosis (25,0 [17,5; 30,0] vs 20,0 [0,0; 25,0], p=0,001). For the first time, a positive relationship was revealed between the severity of carotid atherosclerosis and BAC as follows: women with greater severity of maximum and total carotid stenosis had more severe BAC (p=0,018 and p=0,003, respectively). There was no association between BAC and IMT (p=0,115).Conclusion. BAC is associated with a higher incidence and severity of carotid atheromatosis. A positive relationship was found between the severity of BAC and carotid stenosis. The data obtained confirm the prospects of mammography as a screening technique for identifying individuals with an increased cardiovascular risk.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"24 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139315013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Skripnikova, M. Kolchina, O. Kosmatova, T. Tsoriev, O. Isaykina, O. Drapkina
{"title":"Relationship between parameters of subclinical atherosclerosis and osteoporosis and their prognostic significance: data from the prospective studies","authors":"I. Skripnikova, M. Kolchina, O. Kosmatova, T. Tsoriev, O. Isaykina, O. Drapkina","doi":"10.20996/1819-6446-2023-2958","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2958","url":null,"abstract":"We analyzed modern publications on the relationship between cardiovascular diseases (CVDs) and osteoporosis and, in particular, their preclinical manifestations. Most of the papers on this issue are observational, cross-sectional, or study associations of preclinical markers with disease risk or outcomes. However, the results of these studies do not always coincide and are contradictory. Therefore, it is not possible to define cause-effect relationship between vascular changes and decreased bone mass, as well as persistence of its relationship. Due to the difficulties in management of prospective studies, in the last decade only a few studies have appeared with long-term follow-up of patients without symptoms with subsequent assessment of preclinical manifestations. A strong relationship has been demonstrated between intima-media thickness, plaque presence, coronary artery calcification and low bone density of the spine and proximal femur, as well as between vascular stiffness (pulse wave velocity) and proximal femur bone density. The data obtained indicate combined disorders of vascular wall morphology and bone tissue, not only in postmenopausal women, but also in elderly men, and can be used to justify indications for screening for decreased bone density in patients with CVD. At the same time, larger-scale prospective studies to explore associations between markers of preclinical manifestations of CVD and decreased bone mass, including in the Russian population, are required.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"49 10 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139320881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Kudaev, A. V. Vorobeva, N. L. Lokhovinina, I. T. Abesadze, M. Z. Alugishvili, I. V. Titenkov, M. A. Chernyavsky, A. Panov
{"title":"Perioperative myocardial injury in patients with coronary artery disease during elective lower limb surgery","authors":"Y. Kudaev, A. V. Vorobeva, N. L. Lokhovinina, I. T. Abesadze, M. Z. Alugishvili, I. V. Titenkov, M. A. Chernyavsky, A. Panov","doi":"10.20996/1819-6446-2023-2937","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2937","url":null,"abstract":"Aim. To assess the prevalence of ischemic myocardial injury and the cardioprotective effect of nicorandil by assessing high-sensitivity cardiac troponin (hs-cTn) in patients with stable coronary artery disease (CAD) during elective lower limb surgery, as well as to identify predictors of adverse cardiac events.Material and methods. The study included 70 patients with stable coronary artery disease hospitalized for elective autogenous femoropopliteal bypass (FPB) surgery. After randomization, all patients were divided into two following groups: control group — 35 patients; main group — 35 patients, who, in addition to standard therapy, were prescribed nicorandil (Cordinic, PIQ-PHARMA) in a single dose of 20 mg 2 hours before surgery. In the postoperative period, the incidence of myocardial injury was assessed by hs-cTn increase. The obtained primary data were subjected to mathematical processing using the R-Studio software package (R language).Results. At baseline, patients in both groups were comparable in clinical characteristics, therapy, and duration of vascular surgery. In the main group of patients receiving nicorandil, a significant decrease in the incidence of perioperative myocardial injury was noted. In 5 patients of the control group, hs-cTn level 24 hours after surgery exceeded the threshold value, which indicated myocardial injury in the early postoperative period. In the nicorandil group, there was no hs-cTn increase (14% vs 0%, p=0,027). Regression analysis identified a predictor of perioperative myocardial injury — left ventricular ejection fraction (LVEF) <50%. LVEF <50% increases the risk of myocardial injury in the early postoperative period by 7,36 times (p=0,04) and 9,15 times (p=0,048) according to univariate and multivariate regression analysis, respectively.Conclusion. Perioperative myocardial injury is a common complication in patients with CAD undergoing lower extremity revascularization. The use of nicorandil (Cordinic, PIQ-PHARMA) before elective revascularization surgery helps reduce the incidence of ischemic myocardial injury in the early postoperative period and is not accompanied by adverse reactions, which rationales this approach to improve the clinical outcomes of lower extremity revascularization in patients with stable CAD. A predictor of myocardial injury, determined by hs-cTn, is a LVEF <50%.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139320912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Pronko, V. Snezhitskiy, T. Stepuro, A. Kapytski
{"title":"Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction","authors":"T. Pronko, V. Snezhitskiy, T. Stepuro, A. Kapytski","doi":"10.20996/1819-6446-2023-2904","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2904","url":null,"abstract":"Aim. Study of the association of polymorphic variants of CYP2C19 (G681A), P2RY12 (H1/H2), ITGB3 (T1565C), ITGA2 (C807T), eNOS3 (T786C) genes with high residual platelet reactivity (HRPR) to clopidogrel and acetylsalicylic acid (ASA) at different terms of myocardial infarction (MI).Material and methods. The study included 400 patients with MI aged 31-74 years, 317 (79,3%) men and 83 (20,7%) women. Platelet aggregation performed on days 1-2, 12-14 and 28-30 of MI, and genotyping by the polymerase chain reaction were analyzed using the STATISTICA 10.0 program.Results. Differences were found in ADP-test 1-3 depending on the CYP2C19 (G681A) polymorphism, ADP-test 1 depending on the P2RY12 (H1/H2) polymorphism, ADP-test 2 depending on the ITGB3 (T1565C) polymorphism, ASPI-test 1 depending on the eNOS (T786C) polymorphism. The risk of HRPR to clopidogrel is higher in 681A CYP2C19 allele carriers compared to the G681 carriers throughout the entire observation period: initially odds ratio (OR) of 1,8 (1,14-2,88), p=0,012, on days 12-14 of MI, OR of 1,7 (1,08-2,68), p=0,023 and on days 28-30 of MI, OR of 2,3 (1,42-3,81), p=0,0008. The risk of HRPR to clopidogrel is higher in AA CYP2C19 genotype carriers compared to GG genotype carriers, on days 1-2 of MI (OR 6,5 (1,16-36,4), p=0,033), on days 28-30 of MI (OR 7,8 (1,26-48,0), p=0,027). The risk of HRPR to clopidogrel on days 1-2 of MI is higher in H2 P2RY12 locus carriers compared to H1 locus carriers (OR 1,5 (1,02-2,22), p=0,039). The risk of HRPR to ASA on days 1-2 of MI is higher in the 786C eNOS3 allele carriers compared to T786 allele carriers (OR 1,4 (1,02-1,96), p=0,036). Carriers of haplotypes of minor alleles of CYP2C19 + ITGA2 + P2RY12 + eNOS genes (OR 3,9 (1,13-13,65), p=0,032) and CYP2C19 + ITGA2 + eNOS genes (OR 5,1 (1,7214,96), p=0,0032) have higher risk of HRPR to dual antiplatelet therapy (DAPT) on days 28-30 of MI compared to the rest of patients.Conclusion. The association of HRPR to clopidogrel with the CYP2C19 (G681A) polymorphism was found during the entire observation period, with the P2RY12 (H1/H2) polymorphism on days 1-2 of MI, with the ITGB3 (T1565C) polymorphism on days 10-12 of MI. The association of HRPR to ASA with eNOS (T786C) polymorphism was found on days 1-2 of MI. Minor allele haplotypes of the CYP2C19 + ITGA2 + P2RY12 + eNOS genes and CYP2C19 + ITGA2 + eNOS genes were associated with a higher risk of developing HRPR to DAPT on days 28-30 of MI.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"124 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80196785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Gracheva, E. A. Starovoytova, E. Kulikov, N. Kirillova, S. Fedosenko, M. A. Balaganskaya, D. Kromka
{"title":"Nutraceutical support in the prevention and treatment of cardiovascular diseases","authors":"E. Gracheva, E. A. Starovoytova, E. Kulikov, N. Kirillova, S. Fedosenko, M. A. Balaganskaya, D. Kromka","doi":"10.20996/1819-6446-2023-2909","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2909","url":null,"abstract":"Cardiovascular disease is the most common cause of death worldwide. In this regard, there is a need to find and implement effective methods for the prevention and treatment of such diseases. Lifestyle modification is an important component of a complex of preventive and therapeutic measures, including nutrition optimization, increased physical activity, and breaking bad habits. Currently, an actively developing area is the use of biologically active additives to food, in order to replenish the missing nutrients in the diet and maintain health. In the course of the present review, an analysis was made of randomized clinical trials performed over the past 5 years. The studies investigated both the short-term effects of taking omega-3 polyunsaturated fatty acids (effect on the blood lipid spectrum, blood pressure levels) and longterm results (development of myocardial infarction, stroke, cardiovascular mortality). This supplement has demonstrated a positive effect on immediate outcomes, namely the reduction of total cholesterol, low-density lipoprotein, triglycerides (lipid-lowering effect). However, there was no significant effect on long-term results. It also provides information on studies that have examined the cardioprotective effects of supplements such as resveratrol, red yeast rice, L-arginine, and curcumin. An analysis of publications has shown that these supplements have the potential to reduce the risk of development and progression of cardiovascular diseases due to possible hypolipidemic, endothelial protective, and antihypertensive effects. Nutraceutical support can be an effective addition to the basic treatment and help reduce morbidity and mortality due to cardiovascular disease.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"20 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84895083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. A. Kudriavtseva, E. V. Kolpachkova, Z. A. Gebekova, T. A. Sadulaeva, A. Sokolova, D. Napalkov
{"title":"Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report","authors":"A. A. Kudriavtseva, E. V. Kolpachkova, Z. A. Gebekova, T. A. Sadulaeva, A. Sokolova, D. Napalkov","doi":"10.20996/1819-6446-2023-2900","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2900","url":null,"abstract":"The question of the safety of direct oral anticoagulants (DOACs), despite their high efficacy in the prevention of thrombotic events in atrial fibrillation (AF), remains relevant due to the risk of developing hemorrhagic events while taking standard doses, which requires a thorough personalized approach. The article presents a clinical case of the development of spontaneous hematomas on the skin of the upper and lower extremities and hemarthrosis of the knee joint while taking 20 mg of rivaroxaban in a 72-year-old patient with AF without impaired renal and hepatic function. Due to the increase in the residual plasma concentration of rivaroxaban, a pharmacogenetic study and the Thrombodynamics (TD) test were performed. A pharmacogenetic study did not reveal significant gene polymorphisms associated with the metabolism of rivaroxaban. However, TD allowed us to confirm the presence of significant hypocoagulation at the peak of the residual blood concentration of the drug in the blood, which could cause recurrent hemorrhagic events in the patient. In addition, the patient is taking amiodarone at a dosage of 200 mg per day, which does not allow us to rule out drug-drug interaction, despite the inconsistency of the literature data.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"47 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81686039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Pravkina, E. N. Kochnova, K. Pereverzeva, S. Yakushin
{"title":"Heart failure with improved ejection fraction in patients with tachycardia-induced cardiomyopathy: a case report","authors":"E. Pravkina, E. N. Kochnova, K. Pereverzeva, S. Yakushin","doi":"10.20996/1819-6446-2023-2875","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2875","url":null,"abstract":"Heart failure and arrhythmias are pathogenetically closely interconnected and they are mutually aggravating each other. At the same time, tachycardia-induced cardiomyopathy is particularly a reversible disease with proper treatment. This article presents a case report of an elderly patient with hypertension and atrial fibrillation, which are associated to an advanced heart failure and complicating the management of a decreasing kidneys filtration capacity, hematuria and brain stroke. In this case report, tachycardia-induced cardiomyopathy is caused by persistent atrial fibrillation. A complex approach to diagnosis and evidence-based treatment (in particular cardioversion and radiofrequency ablation) made it possible to restore sinus rhythm and compensate heart failure. Dynamics of the clinical state of the patient, laboratory indicators, echocardiographic characteristics allowed us to retrospectively verify atrial fibrillation-mediated cardiomyopathy as the main cause of heart failure progression, and classify this clinical case as heart failure with improved ejection fraction.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"60 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78138193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. A. Archakov, R. Batalov, M. Khlynin, A. Smorgon, S. Popov
{"title":"Myocardial electroporation — an alternative to thermal methods of atrial fibrillation treatment","authors":"E. A. Archakov, R. Batalov, M. Khlynin, A. Smorgon, S. Popov","doi":"10.20996/1819-6446-2023-2840","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-2840","url":null,"abstract":"Atrial fibrillation is one of the most common cardiac arrhythmias. By all estimates, the number of patients with this arrhythmia will only increase. Currently, the main and most used methods for the treatment of atrial fibrillation are radiofrequency and cryo-balloon ablation. However, the accumulated experience of their use has revealed a number of shortcomings — the lack of long-term pulmonary vein isolation, as well as life-threatening procedure complications. Relatively recent foreign studies showed data on the use of an alternative method of influencing arrhythmogenic foci. The method is based on the use of non-thermal pulsed field ablation, which leads to the appearance of pores in cardiomyocytes and their necrosis, which causes a more stable electrical left atrial pulmonary vein isolation. The margins of the lesions in this exposure are usually very sharp with a narrow transition from normal tissue to tissue with the complete necrosis, while not damaging neighboring structures such as blood vessels, nerves and esophagus. At present, information published in the literature on the use of pulsed field ablation in various fields of medicine, including oncology and cardiology, is clearly not enough. The implementation of this method for the interventional treatment of cardiac arrhythmias is considered a promising direction and is the subject of research by many leading scientific groups around the world. The purpose of this review is to structure the most significant information on the use of pulsed field ablation, presented in the literature, to analyze its possibilities, effectiveness, and disadvantages.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"18 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73634982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}